Enveric Biosciences, Inc. (ENVB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29405E5050

Price
1.52 USD
Market cap
6.80 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-209.98 %
Return on assets (ROA)
-172.14 %

Enveric Biosciences, Inc. financials

Fiscal year20242025
Operating income-9.63 m USD-8.77 m USD
EBIT-9.57 m USD-8.77 m USD
Net income-9.57 m USD-8.77 m USD
Diluted EPS – continuing operations-19.04 USD-36.24 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.